Loading...
Loading...
Cubist
Pharmaceuticals
CBST today announced positive
top-line results from the Company's pivotal Phase 3 clinical trial of
its antibiotic candidate ceftolozane/tazobactam in complicated
intra-abdominal infections (cIAI). Ceftolozane/tazobactam, in
combination with metronidazole, met the U.S. Food and Drug
Administration (FDA) and the European Medicines Agency (EMA) defined
primary endpoints of statistical non-inferiority compared to meropenem.
The primary endpoint was a clinical cure rate 26 - 30 days after the
initiation of therapy (the Test of Cure visit). For the FDA, the primary
analysis was conducted in the Microbiological Intent-to-Treat (MITT)
population; the non-inferiority margin was 10%; and the lower and upper
bounds of the 95% confidence interval were -8.9% and 0.5%, respectively.
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in